<Version>
  <xmlSource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlSource>
  <Section SecID="390" OrdBy="100" Name="General">
    <Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Guidelines for the first line management of classical Hodgkin lymphoma.&lt;/div&gt;" />
    </Field>
    <Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation">
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Follows GA, Ardeshna KM, Barrington SF, Culligan DJ, Hoskin PJ, Linch D, Sadullah S, Williams MV, Wimperis JZ, The British Committee for Standards in Haematology. Guidelines for the first line management of classical Hodgkin lymphoma. Br J Haematol. 2014 Jul;166(1):34-49. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24712411&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
    </Field>
    <Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="420" OrdBy="300" Name="Recommendations">
    <Field FieldID="151" OrdBy="310" ID="421" Name="Major Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Definitions for the quality of the evidence (&lt;strong&gt;A&amp;ndash;C&lt;/strong&gt;) and strength of recommendations (strong [Grade&lt;strong&gt; 1&lt;/strong&gt;], weak [Grade&lt;strong&gt; 2&lt;/strong&gt;]) are given at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Pre-treatment Evaluation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients require pre-treatment blood evaluation including human immunodeficiency virus (HIV) serology (&lt;strong&gt;1A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Staging with contrast-enhanced computed tomography (CT) of the neck to pelvis is required (&lt;strong&gt;1A&lt;/strong&gt;), although positron emission tomography (PET)/CT is preferable if clinically feasible (&lt;strong&gt;1B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Early stage patients should be classified as favourable or unfavourable (&lt;strong&gt;1A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Advanced stage patients should be assessed to define a Hasenclever/International Prognostic Score (IPS) (&lt;strong&gt;1A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;For male patients, pre-treatment semen cryopreservation should be offered where possible (&lt;strong&gt;1A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;For female patients, pre-treatment review of options with a fertility specialist should be considered (&lt;strong&gt;1A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Management of Early Stage Disease&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Prognostic factors should be determined to allocate patients to favourable and unfavourable sub-groups (&lt;strong&gt;1A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Standard of care for patients with favourable early stage Hodgkin lymphoma (HL) is 2 x doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) and 20 Gy radiotherapy (RT) (&lt;strong&gt;1A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Standard of care for unfavourable early stage HL is 4 x ABVD and 30 Gy RT (&lt;strong&gt;1A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A treatment option for unfavourable early stage HL is 2 x escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone (BEACOPP) + 2 x ABVD and 30 Gy RT (&lt;strong&gt;1A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The decision to omit RT from the management of IA/IIA non-bulky patients should involve discussion with a radiation oncologist (&lt;strong&gt;1B&lt;/strong&gt;) and patients choosing to omit RT need to be aware of the balance of risks between RT and additional cycles of chemotherapy (&lt;strong&gt;1B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;RT should not normally be omitted in patients presenting with bulky disease (&lt;strong&gt;1B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Early stage patients treated without RT should receive at least 3 x ABVD (&lt;strong&gt;1B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients receiving bleomycin should be assessed carefully for signs and symptoms of pulmonary toxicity before each dose. A history of new or worsening dyspnoea or pulmonary crackles should lead to stopping of bleomycin until an alternative cause is identified (&lt;strong&gt;1B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Management of Advanced Stage Disease&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients aged 16 to 60 with advanced stage HL should receive either 6 to 8 cycles of ABVD or 6 cycles of escalated BEACOPP (&lt;strong&gt;1A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The choice between ABVD and escalated BEACOPP will depend on a range of factors, particularly the patient's opinion on the toxicity/efficacy balance between the regimens (&lt;strong&gt;2B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with a higher IPS are at higher risk of relapse, potentially supporting the use of escalated BEACOPP in this higher risk group, although there are no prospective trial data to support a specific IPS cut-off at which escalated BEACOPP may be advantageous (&lt;strong&gt;2B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients treated with escalated BEACOPP who achieve an end-of-treatment PET-negative remission do not require consolidation RT to residual tissue (&lt;strong&gt;1A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients treated with ABVD should be considered for RT to sites of original bulk or residual tissue &amp;gt;1.5 cm. It remains unclear whether RT can be safely omitted in ABVD patients who have residual tissue &amp;gt;1.5 cm on CT that is PET-negative (&lt;strong&gt;1A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Interim positron emission tomography (iPET2) is highly predictive of outcome in patients treated with ABVD (&lt;strong&gt;1A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It remains unclear how iPET2 positive patients are optimally managed in routine practice. Accepting the limitations of small published datasets, treatment intensification to escalated BEACOPP &amp;plusmn; RT appears reasonable (&lt;strong&gt;2B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients who remain PET-positive on completion of therapy require biopsy assessment or close clinical/radiological surveillance for early progression (&lt;strong&gt;1B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients who develop progressive disease on therapy should be considered for treatment intensification with transplantation (&lt;strong&gt;1A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Management of HL in Pregnancy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients should be closely co-managed with a specialised obstetric/fetal medicine unit (&lt;strong&gt;1B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Staging investigations and response evaluation should be tailored to the clinical presentation with radiology input to minimise fetal radiation exposure (&lt;strong&gt;1C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Delaying commencement of chemotherapy until post-delivery would not be standard practice and should be done with caution (&lt;strong&gt;1C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;ABVD is the regimen of choice unless specifically contraindicated (&lt;strong&gt;1B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Wherever possible, RT should be delayed until post-delivery (&lt;strong&gt;1B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Management of HL in Elderly Patients&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Elderly patients should be formally assessed for fitness to receive combination chemotherapy with a co-morbidity assessment tool which should distinguish &quot;frail&quot; from &quot;non-frail&quot; patients (&lt;strong&gt;2B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients considered &quot;frail&quot; should not usually be offered conventional combination chemotherapy (&lt;strong&gt;2B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&quot;Non-frail&quot; patients should be offered combination chemotherapy and RT with the aim of achieving complete response (CR), which is associated with better survival (&lt;strong&gt;1B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Older patients receiving bleomycin must be followed very closely for symptoms and signs of bleomycin lung toxicity (&lt;strong&gt;1A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Guidance on therapy choice for &quot;non-frail&quot; patients is hampered by the lack of randomised trial data. Treatment with vinblastine, cyclophosphamide, prednisolone, procarbazine, etoposide, mitoxantrone (VEPEMB) or cyclophosphamide, vincristine, procarbazine, prednisone (COPP)/ABVD appears to have lower treatment-related mortality than ABVD or BEACOPP (&lt;strong&gt;2B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;PET/CT in HL&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;PET/CT should be reported by PET/CT imaging specialists (&lt;strong&gt;1C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;As pre-treatment staging with PET/CT will upstage a minority of patients and aid the interpretation of subsequent PET/CT, it is recommended when clinically feasible (&lt;strong&gt;1B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;PET/CT response should be reported according to Deauville criteria (&lt;strong&gt;2B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;By Deauville criteria, a score of 1 or 2 should be considered &quot;negative&quot; and 4 or 5 considered &quot;positive&quot;. Deauville score 3 should be interpreted according to the clinical context but in many HL patients indicates a good prognosis with standard treatment (&lt;strong&gt;1B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Biopsy is advised prior to second-line therapy to confirm residual disease with score 4 or 5&amp;nbsp;where possible to exclude false positive uptake with fluorodeoxyglucose (FDG) (&lt;strong&gt;1B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The optimal management of iPET2-positive patients remains uncertain. Therefore at this time iPET2 remains desirable for ABVD-treated patients but cannot be mandated as a standard of care (&lt;strong&gt;2B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;If a pre-treatment decision has been made to treat an early stage patient with RT following ABVD, then there is no clear role for interim PET/CT (&lt;strong&gt;1A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;End-of-treatment PET/CT is recommended for all patients who have not achieved an interim PET negative remission as this may directly affect RT planning, biopsy considerations and follow-up strategy (&lt;strong&gt;1B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Radiotherapy Strategies in HL&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The evidence for the role of RT in HL is based on involved field RT (IFRT) (&lt;strong&gt;1A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reduced volume approaches, involved node (INRT) or involved site (ISRT) are under evaluation in current protocols (&lt;strong&gt;2B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The dose for favourable early stage disease should be 20 Gy and 30 Gy for all other patients (&lt;strong&gt;1A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Follow-up, Late Effects and Survivorship&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients are usually followed with intermittent outpatient clinical review for 2 to 5 years following first-line therapy (&lt;strong&gt;2C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;There is no proven role for routine surveillance CT or PET/CT imaging in patients who are otherwise well following first-line therapy (&lt;strong&gt;2B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;HL patients should be made aware that they are at an increased lifetime risk of second neoplasms, cardiovascular and pulmonary disease and infertility (&lt;strong&gt;1A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Apart from the current breast cancer screening programme, there are no national cancer screening programmes tailored for HL survivors. Women treated with mediastinal RT before the age of 35 yrs should be offered entry into the breast cancer National Notification Risk Assessment and Screening programme (NRASP) (&lt;strong&gt;1A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Regular lifestyle advice should be offered to reduce the secondary neoplasms and cardiovascular risk. There should be complete avoidance of smoking and careful management of cardiovascular risks such as hypertension, diabetes mellitus and hyperlipidaemia (&lt;strong&gt;1B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients who have had RT to the neck and upper mediastinum should have regular thyroid function checks. Hypothyroidism can occur up to 30 years after RT (&lt;strong&gt;1A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients should receive irradiated blood products for life (&lt;strong&gt;1B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Quality of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The quality of evidence is graded as high (A), moderate (B) or low (C). To put this in context it is useful to consider the uncertainty of knowledge and whether further research could change what is known or is certain.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;(A) High&lt;/strong&gt;: Further research is very unlikely to change confidence in the estimate of effect. Current evidence derived from randomised clinical trials without important limitations.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;(B) Moderate&lt;/strong&gt;: Further research may well have an important impact on confidence in the estimate of effect and may change the estimate. Current evidence derived from randomised clinical trials with important limitations (e.g., inconsistent results, imprecision &amp;ndash; wide confidence intervals or methodological flaws &amp;ndash; e.g., lack of blinding, large losses to follow up, failure to adhere to intention to treat analysis), or very strong evidence from observational studies or case series (e.g., large or very large and consistent estimates of the magnitude of a treatment effect or demonstration of a dose&amp;ndash;response gradient).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;(C) Low&lt;/strong&gt;: Further research is likely to have an important impact on confidence in the estimate of effect and is likely to change the estimate. Current evidence from observational studies, case series or just opinion.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strength of Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strong (Grade 1)&lt;/strong&gt;: Strong recommendations (Grade 1) are made when there is confidence that the benefits do or do not outweigh harm and burden. Grade 1 recommendations can be applied uniformly to most patients. Regard as &quot;recommend&quot;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Weak (Grade 2)&lt;/strong&gt;: Where the magnitude of benefit or not is less certain a weaker Grade 2 recommendation is made. Grade 2 recommendations require judicious application to individual patients. Regard as &quot;suggest&quot;.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="138" OrdBy="330" ID="423" Name="Clinical Algorithm(s)" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="396" OrdBy="400" Name="Scope">
    <Field FieldID="140" OrdBy="405" ID="397" Name="Disease/Condition(s)" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Hodgkin lymphoma&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="103" OrdBy="410" ID="398" Name="Guideline Category" Type="picklist-many">
      <FieldValue Value="Evaluation" />
      <FieldValue Value="Management" />
      <FieldValue Value="Treatment" />
    </Field>
    <Field FieldID="113" OrdBy="415" ID="399" Name="Clinical Specialty" Type="picklist-many">
      <FieldValue Value="Hematology" />
      <FieldValue Value="Internal Medicine" />
      <FieldValue Value="Oncology" />
      <FieldValue Value="Radiation Oncology" />
    </Field>
    <Field FieldID="114" OrdBy="420" ID="400" Name="Intended Users" Type="picklist-many">
      <FieldValue Value="Advanced Practice Nurses" />
      <FieldValue Value="Nurses" />
      <FieldValue Value="Physician Assistants" />
      <FieldValue Value="Physicians" />
    </Field>
    <Field FieldID="129" OrdBy="425" ID="401" Name="Guideline Objective(s)" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To provide healthcare professionals with clear guidance on the management of patients with classical Hodgkin lymphoma (HL)&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="132" OrdBy="430" ID="402" Name="Target Population" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Patients with classical Hodgkin lymphoma (HL)&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="133" OrdBy="435" ID="403" Name="Interventions and Practices Considered" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Pre-treatment Evaluation&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xA;    &lt;li&gt;Pre-treatment blood evaluation including human immunodeficiency virus (HIV) serology &lt;/li&gt;&#xA;    &lt;li&gt;Staging with contrast-enhanced computed tomography (CT) neck to pelvis &lt;/li&gt;&#xA;    &lt;li&gt;Staging with positron emission tomography (PET)/CT (preferred) &lt;/li&gt;&#xA;    &lt;li&gt;Classification of early stage patients as favourable or unfavourable &lt;/li&gt;&#xA;    &lt;li&gt;Determination of Hasenclever/International Prognostic Score (IPS) in advanced stage patients &lt;/li&gt;&#xA;    &lt;li&gt;Pre-treatment semen cryopreservation for male patients &lt;/li&gt;&#xA;    &lt;li&gt;Pre-treatment review of fertility options for female patients &lt;/li&gt;&#xA;&lt;/ol&gt;&#xA;&lt;p&gt;&lt;strong&gt;Treatment/Management&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xA;    &lt;li&gt;Management of early stage disease&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;        &lt;li&gt;Determination of prognostic factors to allocate patients to favourable and unfavourable sub-groups. &lt;/li&gt;&#xA;        &lt;li&gt;Favourable early stage Hodgkin lymphoma (HL) therapy: 2 x doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) and 20 Gy radiotherapy (RT) &lt;/li&gt;&#xA;        &lt;li&gt;Unfavourable early stage HL therapy: 4 x ABVD and 30 Gy RT or 2 x escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone (BEACOPP) + 2 x ABVD and 30 Gy RT &lt;/li&gt;&#xA;        &lt;li&gt;Omission of RT from management based on discussion with radiation oncologist and patient &lt;/li&gt;&#xA;        &lt;li&gt;Assessing for signs and symptoms of bleomycin-induced pulmonary toxicity &lt;/li&gt;&#xA;    &lt;/ul&gt;&#xA;    &lt;/li&gt;&#xA;    &lt;li&gt;Management of advanced stage disease&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;        &lt;li&gt;ABVD (6 to 8 cycles) &lt;/li&gt;&#xA;        &lt;li&gt;Escalated BEACOPP (6 cycles) &lt;/li&gt;&#xA;        &lt;li&gt;Consolidation RT to sites of original bulk or residual tissue &lt;/li&gt;&#xA;        &lt;li&gt;Interim positron emission tomography (iPET2) &lt;/li&gt;&#xA;        &lt;li&gt;Biopsy assessment or close clinical/radiological surveillance for early progression &lt;/li&gt;&#xA;        &lt;li&gt;Treatment intensification with transplantation for progressive disease &lt;/li&gt;&#xA;    &lt;/ul&gt;&#xA;    &lt;/li&gt;&#xA;    &lt;li&gt;Management of HL in pregnancy&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;        &lt;li&gt;Co-management with a specialised obstetric/fetal medicine unit &lt;/li&gt;&#xA;        &lt;li&gt;Minimisation of fetal radiation exposure (delaying RT until post-delivery) &lt;/li&gt;&#xA;        &lt;li&gt;Delaying commencement of chemotherapy until post-delivery (not standard practice) &lt;/li&gt;&#xA;        &lt;li&gt;ABVD (unless specifically contraindicated) &lt;/li&gt;&#xA;    &lt;/ul&gt;&#xA;    &lt;/li&gt;&#xA;    &lt;li&gt;Management of HL in elderly patients&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;        &lt;li&gt;Assessment of frailty &lt;/li&gt;&#xA;        &lt;li&gt;Combination chemotherapy and RT for &quot;non-frail&quot; patients (do not offer to frail patients) &lt;/li&gt;&#xA;        &lt;li&gt;Assessment for symptoms and signs of bleomycin lung toxicity &lt;/li&gt;&#xA;        &lt;li&gt;Treatment with vinblastine, cyclophosphamide, prednisolone, procarbazine, etoposide, mitoxantrone (VEPEMB) or cyclophosphamide, vincristine, procarbazine, prednisone (COPP)/ABVD &lt;/li&gt;&#xA;    &lt;/ul&gt;&#xA;    &lt;/li&gt;&#xA;    &lt;li&gt;Use of PET/CT in HL management &lt;/li&gt;&#xA;    &lt;li&gt;RT strategies in HL (involved field RT [IFRT], involved node RT [INRT] or involved site RT [ISRT], radiation dosage) &lt;/li&gt;&#xA;    &lt;li&gt;Follow-up strategies&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;        &lt;li&gt;Intermittent outpatient clinical review for 2 to 5 years &lt;/li&gt;&#xA;        &lt;li&gt;CT or PET/CT imaging in patients who are otherwise well following first-line therapy (not recommended) &lt;/li&gt;&#xA;        &lt;li&gt;Patient information concerning increased lifetime risk of second neoplasms, cardiovascular and pulmonary disease and infertility &lt;/li&gt;&#xA;        &lt;li&gt;Entry into the breast cancer National Notification Risk Assessment and Screening programme (NRASP) &lt;/li&gt;&#xA;        &lt;li&gt;Lifestyle advice (for reduction of secondary neoplasms and cardiovascular risk) &lt;/li&gt;&#xA;        &lt;li&gt;Regular thyroid function checks for patients who have received RT &lt;/li&gt;&#xA;        &lt;li&gt;Irradiated blood products for life &lt;/li&gt;&#xA;    &lt;/ul&gt;&#xA;    &lt;/li&gt;&#xA;&lt;/ol&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="134" OrdBy="440" ID="404" Name="Major Outcomes Considered" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Survival rates (overall, progression-free) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Female infertility rates &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Complete response rate &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Morbidity and mortality &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treatment-related toxicity &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" />
    </Field>
  </Section>
  <Section SecID="405" OrdBy="500" Name="Methodology">
    <Field FieldID="109" OrdBy="505" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many">
      <FieldValue Value="Hand-searches of Published Literature (Primary Sources)" />
      <FieldValue Value="Hand-searches of Published Literature (Secondary Sources)" />
      <FieldValue Value="Searches of Electronic Databases" />
    </Field>
    <Field FieldID="135" OrdBy="510" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;MEDLINE and EMBASE were searched systematically for publications in English from January 1990 to June 2013 using key words Hodgkin, Lymphoma, Treatment, Chemotherapy, Radiotherapy. References from relevant publications were also searched.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="136" OrdBy="515" ID="408" Name="Number of Source Documents" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="115" OrdBy="520" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice">
      <FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" />
    </Field>
    <Field FieldID="149" OrdBy="525" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Quality of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The quality of evidence is graded as high (A), moderate (B) or low (C). To put this in context it is useful to consider the uncertainty of knowledge and whether further research could change what is known or is certain.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;(A) High&lt;/strong&gt;: Further research is very unlikely to change confidence in the estimate of effect. Current evidence derived from randomised clinical trials without important limitations.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;(B) Moderate&lt;/strong&gt;: Further research may well have an important impact on confidence in the estimate of effect and may change the estimate. Current evidence derived from randomised clinical trials with important limitations (e.g., inconsistent results, imprecision &amp;ndash; wide confidence intervals or methodological flaws &amp;ndash; e.g., lack of blinding, large losses to follow up, failure to adhere to intention to treat analysis), or very strong evidence from observational studies or case series (e.g., large or very large and consistent estimates of the magnitude of a treatment effect or demonstration of a dose&amp;ndash;response gradient).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;(C) Low&lt;/strong&gt;: Further research is likely to have an important impact on confidence in the estimate of effect and is likely to change the estimate. Current evidence from observational studies, case series or just opinion.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="116" OrdBy="530" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many">
      <FieldValue Value="Systematic Review" />
    </Field>
    <Field FieldID="150" OrdBy="535" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Grading of Recommendations Assessment, Development and Evaluation (GRADE) system was used to quote levels and grades of evidence (see the &quot;Rating Scheme for the Strength of the Evidence&quot; field).&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="112" OrdBy="540" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice">
      <FieldValue Value="Expert Consensus" />
    </Field>
    <Field FieldID="145" OrdBy="545" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The guideline group was selected to be representative of UK-based medical experts and patients' representatives. The writing group produced the draft guideline, which was subsequently revised by consensus by members of the Haemato-Oncology Task Force of the British Committee for Standards in Haematology.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="146" OrdBy="550" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Strength of Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strong (Grade 1)&lt;/strong&gt;: Strong recommendations (Grade 1) are made when there is confidence that the benefits do or do not outweigh harm and burden. Grade 1 recommendations can be applied uniformly to most patients. Regard as &quot;recommend&quot;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Weak (Grade 2)&lt;/strong&gt;: Where the magnitude of benefit or not is less certain a weaker Grade 2 recommendation is made. Grade 2 recommendations require judicious application to individual patients. Regard as &quot;suggest&quot;.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="148" OrdBy="565" ID="417" Name="Cost Analysis" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="104" OrdBy="570" ID="418" Name="Method of Guideline Validation" Type="picklist-choice">
      <FieldValue Value="External Peer Review" />
      <FieldValue Value="Internal Peer Review" />
    </Field>
    <Field FieldID="130" OrdBy="575" ID="419" Name="Description of Method of Guideline Validation" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The guideline was reviewed by a sounding board of approximately 50 United Kingdom (UK) haematologists, the British Committee for Standards in Haematology (BCSH) and comments incorporated where appropriate.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations">
    <Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see the &quot;Major Recommendations&quot; field.)&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations">
    <Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Appropriate first line management of classical Hodgkin lymphoma (HL) &lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The potential risk to fetal development from chemotherapy is likely to be higher in the first trimester. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients receiving bleomycin should be assessed carefully for signs and symptoms of pulmonary toxicity before each dose. Bleomycin toxicity ranges from a measured decrease in diffusion capacity, lung volumes and vital capacity, to pneumonitis with nonspecific patchy opacities to end stage pulmonary fibrosis. Early symptoms and signs are dyspnoea/dry cough and crackles which occur 1 to 9 months after starting treatment and should lead to immediate cessation of the drug until another cause has been identified. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;As there are longer term risks for patients treated with radiotherapy (RT), it is recognised that in some circumstances, clinicians and patients may prefer to treat without, particularly as the majority of IA/IIA non-bulky patients will be cured with chemotherapy alone. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Older patients are more likely to die from non-HL causes, including bleomycin lung toxicity, which was reported in 24% of patients over 60 treated within the North American intergroup trial E2496. Therapy-related toxicity has, therefore, made delivering the 'gold standard' chemotherapies, doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) and bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone (BEACOPP), challenging, especially in the over 70s and the major randomised trials contain only small numbers of elderly patients. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The five-point scale (5-PS) also referred to as the 'Deauville criteria', can be used to assess response during treatment (with an interim scan) and at the end of treatment. To avoid the risk of under-treatment, score 1 and score 2 were used to define a 'negative' scan in the RAPID study. To avoid the risk of over-treatment, scores 4 and 5 were used to define a 'positive' scan in the National Cancer Research Institute (NCRI) RATHL study and in the Italian HD0607 study and scores 1,2,3 to define a 'negative' scan) with initial reports suggesting satisfactory responses for patients treated on trial. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A recent large collaborative British Cohort study found that combined modality treatment (CMT) carried a greater relative risk (RR) for secondary neoplasms than chemotherapy alone. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Depending on the age at treatment and the extent of the radiation field, the 25-year cumulative risk of breast cancer in women treated in childhood or early adulthood with RT is approximately 10% to 33%, compared with a lifetime risk in the UK of 11%. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Myocardial infarction (MI) has been particularly linked to mediastinal RT. Significant and independent increased risk of MI was identified for supradiaphragmatic RT, anthracyclines and vinca-alkaloids. The risk was particularly high for the ABVD regimen and the combination of supradiaphragmatic RT and vincristine without anthracyclines. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Fertility preservation techniques can only be discussed on a case-by-case basis, involving fertility experts and oncologists who can judge the appropriateness of the techniques and the risks of delaying treatment. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Interim positron emission tomography/computed tomography (PET/CT) scans should ideally be performed as long after the last chemotherapy administration as possible to avoid potential false positive uptake. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" />
    </Field>
  </Section>
  <Section SecID="432" OrdBy="900" Name="Qualifying Statements">
    <Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;While the advice and information in these guidelines is believed to be true and accurate at the time of going to press, neither the authors, the British Society for Haematology (BSH) nor the publishers accept any legal responsibility for the content of these guidelines. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The guidance may not be appropriate for all patients with Hodgkin lymphoma (HL) and in all cases individual patient circumstances may dictate an alternative approach. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" />
    </Field>
  </Section>
  <Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline">
    <Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories">
    <Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many">
      <FieldValue Value="Getting Better" />
      <FieldValue Value="Living with Illness" />
    </Field>
    <Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many">
      <FieldValue Value="Effectiveness" />
      <FieldValue Value="Patient-centeredness" />
    </Field>
  </Section>
  <Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability">
    <Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation">
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Follows GA, Ardeshna KM, Barrington SF, Culligan DJ, Hoskin PJ, Linch D, Sadullah S, Williams MV, Wimperis JZ, The British Committee for Standards in Haematology. Guidelines for the first line management of classical Hodgkin lymphoma. Br J Haematol. 2014 Jul;166(1):34-49. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24712411&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
    </Field>
    <Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text">
      <FieldValue Value="2014 Jul" />
    </Field>
    <Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p">
      <FieldValue Value="British Society for Haematology Guidelines - Professional Association" />
    </Field>
    <Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;British Committee for Standards in Haematology&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;British Committee for Standards in Haematology (BCSH) Writing Group&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Writing Group Members&lt;/em&gt;: George A. Follows, Department of Haematology, Addenbrookes Hospital, Cambridge University Teaching Hospitals, UK; Kirit M. Ardeshna, Department of Haematology, University College Hospital London Hospitals NHS Trust, London; Sally F. Barrington, PET Imaging Centre, St Thomas' Division of Imaging, Kings College London; Dominic J. Culligan, Department of Haematology, Aberdeen Royal Infirmary, Aberdeen; Peter J. Hoskin, Mount Vernon Cancer Centre, Northwood, Middlesex; David Linch, Department of Haematology, University College Hospital London Hospitals NHS Trust, London, Department of Haematology, UCL Cancer Institute, University College Centre of Imaging, London; Shalal Sadullah, Department of Haematology James Paget University Hospital, Great Yarmouth; Michael V. Williams, Department of Oncology, Addenbrookes Hospital, Cambridge University Teaching Hospitals, UK; Jennifer Z. Wimperis, Department of Haematology Norfolk and Norwich University Hospital, Norwich&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The authors have no conflicts of interest to declare.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available from the &lt;a href=&quot;http://onlinelibrary.wiley.com/doi/10.1111/bjh.12878/full&quot; title=&quot;British Journal of Haematology Web site&quot;&gt;British Journal of Haematology Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from the British Committee for Standards in Haematology; Email: &lt;a href=&quot;mailto:bcsh@b-s-h.org.uk&quot;&gt;bcsh@b-s-h.org.uk&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on April 30, 2014. The information was verified by the guideline developer on May 28, 2014.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is copyrighted by the British Committee for Standards in Haematology. For more information, contact the BCSH Secretary, 100 White Lion Street, London, UK, N1 9PF; Email: &lt;a href=&quot;mailto:bcsh@b-s-h.org.uk&quot;&gt;bcsh@b-s-h.org.uk&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="99999" OrdBy="99999" Name="Disclaimer">
    <Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text">
      <FieldValue Value="&lt;p&gt;The National Guideline Clearinghouseâ¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the &lt;a href=&quot;/help-and-about/summaries/inclusion-criteria&quot;&gt;NGC Inclusion Criteria&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" />
    </Field>
  </Section>
</Version>